Aaron L. Nelson, MD, PhD; Joshua T. Cohen, PhD; Dan Greenberg, PhD; David M. Kent, MD, MS
Potential Conflicts of Interest: None disclosed.
Requests for Single Reprints: David M. Kent, MD, MS, 800 Washington Street, Box 63, Boston, MA 02111; e-mail, email@example.com.
Current Author Addresses: Dr. Nelson: Novartis Institutes for Biomedical Research, 100 Technology Square, Room 4304, Cambridge, MA 02139.
Dr. Greenberg: Department of Health Systems Management, Ben-Gurion University of the Negev, PO Box 653, Beer-Sheva 84105, Israel.
Drs. Cohen and Kent: 800 Washington Street, Box 63, Boston, MA 02111.
Author Contributions: Conception and design: A.L. Nelson, D. Greenberg, D.M. Kent.
Analysis and interpretation of the data: A.L. Nelson, J.T. Cohen, D. Greenberg, D.M. Kent.
Drafting of the article: A.L. Nelson, D. Greenberg, D.M. Kent.
Critical revision of the article for important intellectual content: A.L. Nelson, J.T. Cohen, D. Greenberg, D.M. Kent.
Final approval of the article: A.L. Nelson, J.T. Cohen, D. Greenberg, D.M. Kent.
Statistical expertise: D. Greenberg.
Administrative, technical, or logistic support: A.L. Nelson, D.M. Kent.
Collection and assembly of data: J.T. Cohen.
Under conditions of constrained resources, cost-saving innovations may improve overall outcomes, even when they are slightly less effective than available options, by permitting more efficient reallocation of resources. The authors systematically reviewed all MEDLINE-cited cost–utility analyses written in English from 2002 to 2007 to identify and describe cost- and quality-decreasing medical innovations that might offer favorable “decrementally” cost-effective tradeoffs—defined as saving at least $100 000 per quality-adjusted life-year lost. Of 2128 cost-effectiveness ratios from 887 publications, only 9 comparisons (0.4% of total) described 8 innovations that were deemed to be decrementally cost-effective. Examples included percutaneous coronary intervention (instead of coronary artery bypass graft) for multivessel coronary disease, repetitive transcranial magnetic stimulation (instead of electroconvulsive therapy) for drug-resistant major depression, watchful waiting for inguinal hernias, and hemodialyzer sterilization and reuse. On a per-patient basis, these innovations yielded savings from $122 to almost $12 000 but losses of 0.001 to 0.021 quality-adjusted life-years (approximately 8 hours to 1 week). These findings demonstrate the rarity of decrementally cost-effective innovations in the medical literature.
Nelson AL, Cohen JT, Greenberg D, Kent DM. Much Cheaper, Almost as Good: Decrementally Cost-Effective Medical Innovation. Ann Intern Med. 2009;151:662–667. doi: 10.7326/0003-4819-151-9-200911030-00011
Download citation file:
Published: Ann Intern Med. 2009;151(9):662-667.
Healthcare Delivery and Policy.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use